Breast Cancer — Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
Citation(s)
A Phase I Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer